Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.75 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.67 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | IL2 | P60568 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945567 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL4187277 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL4187272 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL15533442 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL18022555 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL8388035 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL16689576 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL17623940 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL15589634 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL16785939 | 1.00 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183408-A1 | COMBINED ENTEROTOXIGENIC ESCHERICHIA COLI AND SHIGELLA RECOMBINANT | The United States of America as Represented by The Secretary of the Navy (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11077200-B2 | Combined enteropathogen recombinant construct | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3063288-B1 | A METHOD FOR LABELING SPECIFICALLY LIVING BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2020-12-02 | — | — | EP | disclosed |
| US-20190167779-A1 | Synthetic Antigen Constructs Against Campylobacter Jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190008979-A1 | Combined enteropathogen recombinant construct | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2019-01-10 | — | — | US | disclosed |
| US-10105448-B2 | Combined enteropathogen recombinant construct | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2018-10-23 | — | — | US | disclosed |
| US-10082509-B2 | Method for labeling specifically living and bacteria comprising the use of modified monosaccharide compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-09-25 | — | — | US | disclosed |
| EP-3370753-A1 | SYNTHETIC ANTIGEN CONSTRUCTS AGAINST CAMPYLOBACTER JEJUNI | The United States of America as Represented by the Secretary of the Navy (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180177857-A1 | Synthetic Antigen Constructs Against Campylobacter Jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2018-06-28 | — | — | US | disclosed |
| US-9925254-B2 | Synthetic antigen constructs against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3063288-A1 | A METHOD FOR LABELING SPECIFICALLY LIVING BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2016-09-07 | — | — | EP | disclosed |
| US-20160238609-A1 | A METHOD FOR LABELING SPECIFICALLY LIVING AND BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-18 | — | — | US | disclosed |
| US-20160144017-A1 | Synthetic Antigen Constructs Against Campylobacter Jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2016073773-A1 | SYNTHETIC ANTIGEN CONSTRUCTS AGAINST CAMPYLOBACTER JEJUNI | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016048810-A1 | COMBINED ENTEROTOXIGENIC ESCHERICHIA COLI AND CAMPYLOBACTER JEJUNI RECOMBINANT CONSTRUCT | THE UNITED STATES OF AMERICA AS REPRESENTED BY TH SECRETARY OF THE NAVY (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20150258201-A1 | Combined enteropathogen recombinant construct | GUERRY PATRICIA (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2015063173-A1 | A METHOD FOR LABELING SPECIFICALLY LIVING BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2015-05-07 | — | — | WO | disclosed |
| EP-2868750-A1 | A method for labeling specifically living bacteria comprising the use of modified monosaccharide compounds | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2015-05-06 | — | — | EP | disclosed |
| US-6245902-B1 | USEFUL FOR PREPARING C-GLYCOSIDE ANALOGS OF GANGLIOSIDES, PEPTIDES, AND PROTEINS, AS WELL AS SYNTHETIC INTERMEDIATES USEFUL FOR THE PREPARATION OF THE PRECURSORS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2001-06-12 | — | — | US | disclosed |
| WO-2001010877-A1 | C-GLYCOSIDE ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10105448-B2 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | TYR 4631/4885SLC5A1 4132/4885SLC5A2 3759/4885 |
| US-20150258201-A1 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | TYR 4631/4885SLC5A1 4132/4885SLC5A2 3759/4885 |
| US-11077200-B2 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | TYR 4631/4885SLC5A1 4132/4885SLC5A2 3759/4885 |
| US-20180177857-A1 | Synthetic Antigen Constructs Against Campylobacter Jejuni | LGALS3BP, LGALS2, ST3GAL3 | TYR 1225/4885SLC5A1 2480/4885SLC5A2 1906/4885 |
| US-20190008979-A1 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | TYR 4631/4885SLC5A1 4132/4885SLC5A2 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.